NovaBay Pharmaceuticals Q1 2025 Revenue at $5.5M
Ticker: NBY · Form: 10-Q · Filed: May 15, 2025 · CIK: 1389545
Sentiment: neutral
Topics: 10-Q, revenue, divestiture, financials
TL;DR
NovaBay Q1 revenue $5.5M, divested Avenova assets Jan 17.
AI Summary
NovaBay Pharmaceuticals, Inc. filed its Q1 2025 10-Q report on May 15, 2025, detailing financial performance for the quarter ending March 31, 2025. The company reported revenue of $5.5 million for the period. A significant event noted is the disposal of Avenova Assets, which occurred on January 17, 2025, and is classified under 'DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember'.
Why It Matters
This filing provides insight into NovaBay's financial health and strategic divestitures, impacting investor understanding of its current operational focus and asset base.
Risk Assessment
Risk Level: medium — The company's financial performance and asset disposals indicate potential shifts in business strategy and revenue streams, requiring careful monitoring.
Key Numbers
- $5.5M — Revenue (Reported for the first quarter of 2025.)
- 2025-03-31 — Reporting Period End Date (The end date for the financial quarter covered by this 10-Q.)
- 2025-05-15 — Filing Date (The date the 10-Q report was officially filed with the SEC.)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250515 (date) — Filing date of the report
- $5.5 million (dollar_amount) — Revenue for Q1 2025
- Avenova Assets (company) — Assets disposed of by sale
- January 17, 2025 (date) — Date of Avenova Assets disposal
- Dermadoctor (company) — Discontinued operations disposed of by sale
- WoundCare (company) — Disposal group disposed of by sale
FAQ
What was NovaBay Pharmaceuticals' total revenue for the first quarter of 2025?
NovaBay Pharmaceuticals reported revenue of $5.5 million for the first quarter of 2025.
When were the Avenova Assets disposed of by NovaBay Pharmaceuticals?
The Avenova Assets were disposed of by sale on January 17, 2025.
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is for the quarter ended March 31, 2025.
What other business segments or assets were disposed of by NovaBay Pharmaceuticals?
The filing mentions the disposal of Dermadoctor and WoundCare assets as part of discontinued operations or disposal groups.
On what date was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 15, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding NovaBay Pharmaceuticals, Inc. (NBY).